Roxithromycin in the therapy of Streptococcus pyogenes throat infections.
Roxithromycin in two dosage regimens was compared with erythromycin in the therapy of 227 patients with throat infectious due to Streptococcus pyogenes. All three groups had the same clinical efficacy but roxithromycin 300 mg daily was less effective than erythromycin 500 mg qds in eradicating S. pyogenes while there were less antibiotic-related side effects with roxithromycin 150 mg bd than with erythromycin.
Herron
J M
JM
Arkansas Research Medical Testing Center, Little Rock.
D000293:Adolescent; D000328:Adult; D000368:Aged; D004917:Erythromycin / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007933:Leucomycins / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010608:Pharyngeal Diseases / Q000188:drug therapy* / Q000382:microbiology; D012141:Respiratory Tract Infections / Q000188:drug therapy; D013290:Streptococcal Infections / Q000188:drug therapy* / Q000382:microbiology; D013297:Streptococcus pyogenes
D007933:Leucomycins; D004917:Erythromycin